Cambridge Antibody Tech Group PLC
19 May 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
John Stocker
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
274
8) Percentage of issued class
0.0005%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£5.69
13) Date of transaction
19 May 2005
14) Date company informed
19 May 2005
15) Total holding following this notification
82,460
16) Total percentage holding of issued class following this notification
0.160
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis. The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..19 May 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Ake Stavling
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
274
8) Percentage of issued class
0.0005%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£5.69
13) Date of transaction
19 May 2005
14) Date company informed
19 May 2005
15) Total holding following this notification
2,616
16) Total percentage holding of issued class following this notification
0.005%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis. The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..19 May 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Sir Aaron Klug
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
274
8) Percentage of issued class
0.0005%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£5.69
13) Date of transaction
19 May 2005
14) Date company informed
19 May 2005
15) Total holding following this notification
28,201
16) Total percentage holding of issued class following this notification
0.055%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis. The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..19 May 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Peter Ringrose
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
274
8) Percentage of issued class
0.0005%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£5.69
13) Date of transaction
19 May 2005
14) Date company informed
19 May 2005
15) Total holding following this notification
3,436
16) Total percentage holding of issued class following this notification
0.007%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis. The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..19 May 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Professor Christopher Marshall
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
274
8) Percentage of issued class
0.0005%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£5.69
13) Date of transaction
19 May 2005
14) Date company informed
19 May 2005
15) Total holding following this notification
501
16) Total percentage holding of issued class following this notification
0.001%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis. The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..19 May 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Dr Paul Nicholson
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Dr Paul Nicholson
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
659
8) Percentage of issued class
0.0013%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£5.69
13) Date of transaction
19 May 2005
14) Date company informed
19 May 2005
15) Total holding following this notification
10,269
16) Total percentage holding of issued class following this notification
0.019%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis. The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..19 May 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Professor Uwe Bicker
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Professor Uwe Bicker
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
274
8) Percentage of issued class
0.0005%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£5.69
13) Date of transaction
19 May 2005
14) Date company informed
19 May 2005
15) Total holding following this notification
6,319
16) Total percentage holding of issued class following this notification
0.012%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis. The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..19 May 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.